68Ga-FAPI-46 PET/CT

DIAGNOSTIC_TEST4 trials

Sponsors

The National Center of Oncology, Azerbaijan, Institut Curie, European Institute of Oncology, Centre Hospitalier Universitaire Vaudois

Conditions

Breast Cancer InvasiveBreast NeoplasmsFAPIFibroblast Activation Protein InhibitorFluorodeoxyglucose F18Molecular ImagingNode Positive Breast CancerPET / CT

Phase 2

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Active, not recruitingNCT06175390

Institut CurieTriple Negative Breast Cancer

Start: 2024-03-27End: 2029-02-15Updated: 2026-02-06

Unknown Phase

Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma

The National Center of Oncology, AzerbaijanBreast Neoplasms, Fibroblast Activation Protein Inhibitor, Fluorodeoxyglucose F18 +1

Start: 2021-02-04End: 2022-12-31Target: 100Updated: 2022-06-24

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer

RecruitingNCT06790264

European Institute of OncologyBreast Cancer Invasive, Node Positive Breast Cancer

Start: 2024-11-01End: 2025-11-30Target: 92Updated: 2025-01-27

68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma

Not yet recruitingNCT06911021

Centre Hospitalier Universitaire VaudoisFAPI, Molecular Imaging, Pancreatic Adenocarcinoma +2

Start: 2025-05-01End: 2027-12-31Target: 20Updated: 2025-04-04

Related Papers

Abstract P2-12-23: A phase 2 trial combining tiragolumab and atezolizumab with neoadjuvant or first line chemotherapy for triple negative breast cancer (SKYLINE)

Clinical Cancer Research2025-06-13